Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 192 Lymphoma 102 Lymphoma, Non-Hodgkin 90 Leukemia, Myeloid, Acute 89 Precursor Cell Lymphoblastic Leukemia-Lymphoma 81 Myelodysplastic Syndromes 81 Hodgkin Disease 67 Leukemia 66 Neoplasms, Plasma Cell 65 Lymphoma, Large B-Cell, Diffuse 59 Leukemia, Lymphocytic, Chronic, B-Cell 58 Lymphoma, Mantle-Cell 52 Lymphoma, Follicular 49 Burkitt Lymphoma 39 Lymphoma, Large-Cell, Immunoblastic 35 Lymphoma, B-Cell, Marginal Zone 34 Myeloproliferative Disorders 30 Recurrence 28 Hematologic Neoplasms 28 Neuroblastoma 25 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25 Leukemia, Myeloid, Accelerated Phase 24 Graft vs Host Disease 23 Leukemia, Myelomonocytic, Chronic 22 Leukemia, Myeloid, Chronic-Phase 22 Congenital Abnormalities 21 Immunoglobulin Light-chain Amyloidosis 20 Dendritic Cell Sarcoma, Interdigitating 19 Primary Myelofibrosis 18 Waldenstrom Macroglobulinemia 17

Interventions

Melphalan 1 Lenograstim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Castrate Resistant Prostate Cancer × Melphalan × Clear all

NCT01907009 2023-04-19

MEL-CAP

Barts & The London NHS Trust

Phase 2/3 Terminated

Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡